Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science (ICMS), Fujita Health University, Toyoake, Aichi, Japan.
Am J Physiol Endocrinol Metab. 2011 Mar;300(3):E543-53. doi: 10.1152/ajpendo.00430.2010. Epub 2011 Jan 4.
Myostatin, a member of the transforming growth factor (TGF)-β superfamily, plays a potent inhibitory role in regulating skeletal muscle mass. Inhibition of myostatin by gene disruption, transgenic (Tg) expression of myostatin propeptide, or injection of propeptide or myostatin antibodies causes a widespread increase in skeletal muscle mass. Several peptides, in addition to myostatin propeptide and myostatin antibodies, can bind directly to and neutralize the activity of myostatin. These include follistatin and follistatin-related gene. Overexpression of follistatin or follistatin-related gene in mice increased the muscle mass as in myostatin knockout mice. Follistatin binds to myostatin but also binds to and inhibits other members of the TGF-β superfamily, notably activins. Therefore, follistatin regulates both myostatin and activins in vivo. We previously reported the development and characterization of several follistatin-derived peptides, including FS I-I (Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K. FASEB J 22: 477-487, 2008). FS I-I retained myostatin-inhibitory activity without affecting the bioactivity of activins. Here, we found that inhibition of myostatin increases skeletal muscle mass and decreases fat accumulation in FS I-I Tg mice. FS I-I Tg mice also showed decreased fat accumulation even on a control diet. Interestingly, the adipocytes in FS I-I Tg mice were much smaller than those of wild-type mice. Furthermore, FS I-I Tg mice were resistant to high-fat diet-induced obesity and hepatic steatosis and had lower hepatic fatty acid levels and altered fatty acid composition compared with control mice. FS I-I Tg mice have improved glucose tolerance when placed on a high-fat diet. These data indicate that inhibiting myostatin with a follistatin-derived peptide provides a novel therapeutic option to decrease adipocyte size, prevent obesity and hepatic steatosis, and improve glucose tolerance.
肌肉生长抑制素(Myostatin)是转化生长因子(TGF)-β超家族的成员,在调节骨骼肌质量方面发挥着强大的抑制作用。通过基因敲除、转基因(Tg)表达肌肉生长抑制素前肽或注射前肽或肌肉生长抑制素抗体抑制肌肉生长抑制素,会导致骨骼肌质量广泛增加。除了肌肉生长抑制素前肽和肌肉生长抑制素抗体之外,还有几种肽可以直接结合并中和肌肉生长抑制素的活性。这些包括卵泡抑素和卵泡抑素相关基因。在小鼠中过表达卵泡抑素或卵泡抑素相关基因会增加肌肉质量,就像肌肉生长抑制素敲除小鼠一样。卵泡抑素与肌肉生长抑制素结合,但也与 TGF-β 超家族的其他成员(特别是激活素)结合并抑制其活性。因此,卵泡抑素在体内调节肌肉生长抑制素和激活素。我们之前报道了几种卵泡抑素衍生肽的开发和表征,包括 FS I-I(Nakatani M、Takehara Y、Sugino H、Matsumoto M、Hashimoto O、Hasegawa Y、Murakami T、Uezumi A、Takeda S、Noji S、Sunada Y、Tsuchida K.FASEB J 22: 477-487, 2008)。FS I-I 保留了肌肉生长抑制素抑制活性,而不影响激活素的生物活性。在这里,我们发现抑制肌肉生长抑制素会增加骨骼肌质量并减少 FS I-I Tg 小鼠的脂肪堆积。即使在正常饮食下,FS I-I Tg 小鼠也表现出脂肪堆积减少。有趣的是,FS I-I Tg 小鼠的脂肪细胞比野生型小鼠小得多。此外,FS I-I Tg 小鼠对高脂肪饮食引起的肥胖和肝脂肪变性具有抗性,并且与对照小鼠相比,其肝脂肪酸水平较低且脂肪酸组成发生改变。FS I-I Tg 小鼠在高脂肪饮食时的葡萄糖耐量得到改善。这些数据表明,用卵泡抑素衍生肽抑制肌肉生长抑制素为减少脂肪细胞大小、预防肥胖和肝脂肪变性以及改善葡萄糖耐量提供了一种新的治疗选择。